Moderna raises full-year COVID vaccine sales forecast to $21 billion
March 24, 2022; 7:33 AM EDT
(Reuters) – Moderna Inc (MRNA.O) on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21 billion from $19 billion.
The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.
Moderna on Thursday forecast additional purchases of roughly $500 million.
Our Standards: The Thomson Reuters Trust Principles.